Specifications for biotechnology-derived protein drugs

被引:10
|
作者
Seamon, KB [1 ]
机构
[1] Immunex Corp, Drug Dev, Seattle, WA 98101 USA
关键词
D O I
10.1016/S0958-1669(98)80067-0
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Specifications are the regulatory and legal standards that a product must meet to be suitable for use in humans. Specifications evolve in parallel with drug development and are refined prior to marketing authorization and, in some cases, after marketing. Recent changes in regulatory procedures for biotechnology-derived protein products have placed much emphasis on the use of characterization and final product specifications to provide assurance of overall quality of these products. In addition, harmonized guidelines for the testing and specifications for biotechnology products have been developed through the international Conference on Harmonization process. The availability of sensitive, quantitative, and specific analytical methods for characterization has made this possible, thus providing regulatory flexibility in the development of biotechnology-derived protein products. Further refinement of these analytical tools will undoubtedly enhance this regulatory flexibility.
引用
收藏
页码:319 / 325
页数:7
相关论文
共 50 条
  • [1] FDA CONCERNS WITH BIOTECHNOLOGY-DERIVED DRUGS BIOLOGICS
    MACKLER, BF
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1984, 188 (AUG): : 24 - MBTD
  • [2] Biotechnology-derived drugs: how far has Morocco come?
    Zaoui, Sanaa
    Habchane, Amal
    Khatem, Soukaina
    Alioua, Ayyoub
    [J]. PAN AFRICAN MEDICAL JOURNAL, 2022, 43
  • [3] A rational approach for setting and maintaining specifications for biological and biotechnology-derived products - Part 2
    Schofield, Timothy
    Apostol, Izydor
    Koeller, Gerhard
    Powers, Susan
    Stawicki, Mary
    Wolfe, Richard A.
    [J]. BIOPHARM INTERNATIONAL, 2008, 21 (07) : 32 - +
  • [4] A rational approach for setting and maintaining specifications for biological and biotechnology-derived products - Part 1
    Apostol, Izydor
    Schofield, Timothy
    Koeller, Gerhard
    Powers, Susan
    Stawicki, Mary
    Wolfe, Richard A.
    [J]. BIOPHARM INTERNATIONAL, 2008, 21 (06) : 42 - +
  • [5] Public acceptance of biotechnology-derived products
    Hoban, TJ
    [J]. GENETICS AND THE FUTURE OF TOBACCO, PROCEEDINGS, 1999, 25 : 61 - 80
  • [6] Biotechnology-derived cardiovascular therapeutics and toxicity
    Y. James
    [J]. Cardiovascular Toxicology, 2003, 3 (1) : 1 - 3
  • [7] BIOTECHNOLOGY-DERIVED FOODS FROM ANIMALS
    HESS, CE
    [J]. CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 1992, 32 (02) : 147 - 150
  • [8] PROSPECTS FOR APPLICATION OF BIOTECHNOLOGY-DERIVED BIOMATERIALS
    HELLMAN, KB
    PICCIOLO, GL
    FOX, CF
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, 56 (02) : 210 - 224
  • [9] Capillary electrophoresis of biotechnology-derived proteins
    Strege, MA
    Lagu, AL
    [J]. ELECTROPHORESIS, 1997, 18 (12-13) : 2343 - 2352
  • [10] A rational approach for setting and maintaining specifications for biological and biotechnology-derived products. Part 3
    Schofield, Timothy
    Apostol, Izydor
    Koeller, Gerhard
    Powers, Susan
    Stawicki, Mary
    Wolfe, Richard A.
    [J]. BIOPHARM INTERNATIONAL, 2008, 21 (08) : 44 - +